Compare · FMS vs MRAI
FMS vs MRAI
Side-by-side comparison of Fresenius Medical Care AG (FMS) and Marpai Inc. (MRAI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and MRAI operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $13.13B, about 301.6x MRAI ($43.5M).
- FMS has been more active in the news (7 items in the past 4 weeks vs 4 for MRAI).
- FMS has more recent analyst coverage (23 ratings vs 0 for MRAI).
- Company
- Fresenius Medical Care AG
- Marpai Inc.
- Price
- $23.50-0.04%
- $0.92-55.67%
- Market cap
- $13.13B
- $43.5M
- 1M return
- -5.62%
- -
- 1Y return
- -7.83%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 4
- Recent ratings
- 23
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Marpai Inc.
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market. It also offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. The company was incorporated in 2021 and is based in Tampa, Florida.
Latest FMS
- Amendment: SEC Form SCHEDULE 13D/A filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery
- Fresenius Medical Care accelerates income growth to 23% in the second quarter of 2026 while advancing its strategic agenda
- Fresenius Medical Care announces BEACON-US, generating real-world evidence supporting high-volume hemodiafiltration for U.S. dialysis patients
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical downgraded by BNP Paribas Exane with a new price target
Latest MRAI
- Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients
- Marpai Reports Second Quarter 2026 Financial Results
- New insider Mitchell Calvin Steven claimed ownership of 750,000 shares (SEC Form 3)
- SEC Form 10-Q filed by Marpai Inc.
- Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Marpai Announces $12 Million Private Placement led by Mitchell Companies
- Marpai Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Marpai Inc. Announces Debt Restructuring Agreements with JGB Capital and AXA, Reducing Debt Service by $26.4 Million Through 2027 and Enhances Near term Liquidity
- Director Eitan Yaron returned 50,000 shares to the company and was granted 175,000 shares, decreasing direct ownership by 4% to 1,224,073 units (SEC Form 4)
- Chief Financial Officer Johnson Steve Andrew was granted 125,000 shares and bought $682 worth of shares (1,100 units at $0.62), increasing direct ownership by 14% to 1,024,192 units (SEC Form 4)